Signal Genetics is seeking licensing partners to further develop BreastPRS as a stand-alone prognostic test for patients with breast cancer. For more information contact Signal Genetics by emailing info(at)signalgenetics(dot)com.
 Timothy M. D’Alfonso, et al. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence. Breast Cancer Research and Treatment. June 2013, Volume 139, Issue 3, pp 705-715
Genomic Health and Oncotype DX are registered trademarks of Genomic Health, Inc.
Read the full story at http://www.prweb.com/releases/signalgenetics/breastprs/prweb10947060.htm.
Copyright©2012 Vocus, Inc.
All rights reserved